Martin Reck

Research.com Recognitions

• 2023 - Research.com Medicine in Spain Leader Award

Overview

Best Publications

• Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †

  S Novello;F Barlesi;R Califano;R Califano;T Cufer

  2325
  Citations

• Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

  Martin Reck;Joachim von Pawel;Petr Zatloukal;Rodryg Ramlau

  1901
  Citations

• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

  Edward S. Kim;Vera Hirsh;Tony Mok;Mark A. Socinski

  1743
  Citations

• Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

  Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  1377
  Citations

• Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

  Thomas J. Lynch;Igor Bondarenko;Alexander Luft;Piotr Serwatowski

  1340
  Citations

• Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

  Martin Reck;Rolf Kaiser;Anders Mellemgaard;Jean-Yves Douillard

  1116
  Citations

• Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

  Edward B. Garon;Tudor Eliade Ciuleanu;Oscar Arrieta;Kumar Prabhash

  1060
  Citations

• First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

  Luis Paz-Ares;Tudor-Eliade Ciuleanu;Manuel Cobo;Michael Schenker

  1039
  Citations

• Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

  Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

  946
  Citations

• Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

  Martin Reck;Tony S K Mok;Makoto Nishio;Robert M Jotte

  932
  Citations

• Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

  Shirish Gadgeel;Delvys Rodríguez-Abreu;Giovanna Speranza;Emilio Esteban

  880
  Citations

• Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  M Reck;S Popat;N Reinmuth;Dirk De Ruysscher

  827
  Citations

• Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

  M. Reck;J Von Pawel;P. Zatloukal;R. Ramlau

  823
  Citations

• Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

  M. Reck;I. Bondarenko;A. Luft;P. Serwatowski

  815
  Citations

• Management of non-small-cell lung cancer: recent developments.

  Martin Reck;David F. Heigener;Tony Mok;Jean Charles Soria

  810
  Citations

• Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

  Luis Paz-Ares;Filippo de Marinis;Mircea Dediu;Michael Thomas

  804
  Citations

• PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

  Luis G. Paz-Ares;Filippo de Marinis;Mircea Dediu;Michael Thomas

  754
  Citations

• Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%

  Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  693
  Citations

• Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

  Jean Yves Douillard;Frances A. Shepherd;Vera Hirsh;Tony Mok

  628
  Citations

• Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

  Christian Rolfo;Philip C. Mack;Giorgio V. Scagliotti;Paul Baas

  599
  Citations